Advaxis, Inc. (ADXS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADXS Stock Summary
- ADVAXIS INC's market capitalization of $6,580,117 is ahead of just 2.56% of US-listed equities.
- With a year-over-year growth in debt of -70%, ADVAXIS INC's debt growth rate surpasses only 3.24% of about US stocks.
- Revenue growth over the past 12 months for ADVAXIS INC comes in at -92.28%, a number that bests only 1.19% of the US stocks we're tracking.
- Stocks that are quantitatively similar to ADXS, based on their financial statements, market capitalization, and price volatility, are SPOK, RBBN, GEOS, RMED, and LODE.
- Visit ADXS's SEC page to see the company's official filings. To visit the company's web site, go to www.advaxis.com.
ADXS Valuation Summary
- In comparison to the median Healthcare stock, ADXS's price/earnings ratio is 102.21% lower, now standing at -0.5.
- Over the past 215 months, ADXS's price/sales ratio has gone down 114.
Below are key valuation metrics over time for ADXS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ADXS | 2023-03-17 | 30.0 | 0.3 | -0.5 | 1.2 |
| ADXS | 2023-03-16 | 27.2 | 0.3 | -0.4 | 1.3 |
| ADXS | 2023-03-15 | 31.2 | 0.3 | -0.5 | 1.2 |
| ADXS | 2023-03-14 | 29.2 | 0.3 | -0.5 | 1.3 |
| ADXS | 2023-03-13 | 34.0 | 0.4 | -0.6 | 1.2 |
| ADXS | 2023-03-10 | 32.8 | 0.3 | -0.5 | 1.2 |
ADXS Growth Metrics
- The 3 year net income to common stockholders growth rate now stands at 56.79%.
- Its year over year net cashflow from operations growth rate is now at 13.92%.
- The 2 year net cashflow from operations growth rate now stands at 49.64%.
The table below shows ADXS's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 0.25 | -15.284 | -15.384 |
| 2022-06-30 | 0.25 | -16.043 | -16.237 |
| 2022-03-31 | 0.5 | -14.995 | -12.608 |
| 2021-12-31 | 1.625 | -16.791 | -14.25 |
| 2021-12-31 | 1.625 | -16.791 | -14.25 |
| 2021-09-30 | 3.24 | -15.439 | -17.862 |
ADXS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ADXS has a Quality Grade of D, ranking ahead of 5.96% of graded US stocks.
- ADXS's asset turnover comes in at 0.068 -- ranking 297th of 681 Pharmaceutical Products stocks.
- ZYNE, VTVT, and ENZN are the stocks whose asset turnover ratios are most correlated with ADXS.
The table below shows ADXS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-07-31 | 0.068 | 1 | -4.680 |
| 2021-04-30 | 0.066 | 1 | -2.396 |
| 2021-01-31 | 0.044 | 1 | -1.651 |
| 2020-10-31 | 0.006 | 1 | -1.806 |
| 2020-07-31 | 0.006 | 1 | -2.436 |
| 2020-04-30 | 0.005 | 1 | -3.585 |
ADXS Price Target
For more insight on analysts targets of ADXS, see our ADXS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $2.25 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ADXS Stock Price Chart Interactive Chart >
ADXS Price/Volume Stats
| Current price | $1.35 | 52-week high | $10.71 |
| Prev. close | $1.50 | 52-week low | $1.00 |
| Day low | $1.30 | Volume | 1,000 |
| Day high | $1.40 | Avg. volume | 7,684 |
| 50-day MA | $1.83 | Dividend yield | N/A |
| 200-day MA | $2.42 | Market Cap | 2.45M |
Advaxis, Inc. (ADXS) Company Bio
Advaxis Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology. The company was founded in 2002 and is based in Princeton, New Jersey.
Latest ADXS News From Around the Web
Below are the latest news stories about ADVAXIS INC that investors may wish to consider to help them evaluate ADXS as an investment opportunity.
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring CommitteeRegistration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Updated data on AL102 Phase 2 segment of RINGSIDE are planned for presentation at a medical meeting in 2023 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that the Independent Data Monitoring Committee (IDMC) for its Phase 2/3 RINGSIDE study evaluating investigational new drug AL102 in desmo |
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022. Management Commentary “We were pleased to close our previously announced merger in January 2023,” said Kenneth A. Berlin, President and Chief Executive Officer of the Company. “Our immediate pri |
Advaxis and Ayala Pharmaceuticals Complete MergerREHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small |
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate CancerDose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no serious adverse events reportedFour out of six patients treated are still on study and PSA values are being followed up MONMOUTH JUNCTION, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced an update |
Ayala Pharmaceuticals and Advaxis Enter into Merger AgreementMerger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmace |
ADXS Price Returns
| 1-mo | -10.00% |
| 3-mo | 25.58% |
| 6-mo | -37.35% |
| 1-year | -86.29% |
| 3-year | -96.98% |
| 5-year | -99.94% |
| YTD | 12.50% |
| 2022 | -90.36% |
| 2021 | -55.38% |
| 2020 | -59.34% |
| 2019 | -69.91% |
| 2018 | -93.31% |
Continue Researching ADXS
Here are a few links from around the web to help you further your research on Advaxis Inc's stock as an investment opportunity:Advaxis Inc (ADXS) Stock Price | Nasdaq
Advaxis Inc (ADXS) Stock Quote, History and News - Yahoo Finance
Advaxis Inc (ADXS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...